Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Por Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Publicado em 2015-08-01

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.

Por Bajetta, E., Zilembo, N., Buzzoni, R., Noberasco, C., Di Leo, A., Bartoli, C., Merson, M., Sacchini, V., Moglia, D., Celio, L.
Publicado em 1994

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Por Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchi, A.
Publicado em 1995

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Por Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM
Publicado em 2014-05-01